FBSA-Based Therapeutic and Radioimaging Conjugates Targeting Carbonic Anhydrase Positive Cancers

  • TRL
  • 4

Abstract

Cancer is a deadly disease that affects many people around the world. However, current chemotherapy is associated with a litany of unwanted side effects. In addition, existing treatment does not diagnose malignant stages fast enough for effective treatment. There is need of a method for reducing both the time of diagnosis and the side effects associated with traditional chemotherapy. Researchers at Purdue University have developed a small molecule drug conjugate (SMDC) for cancer treatment. The drug would provide an option for patients who want to achieve early diagnosis and better treat tumors by avoiding the many side effects of traditional chemotherapy like nausea and hair loss. This drug would target chemotherapy drugs and radioimaging agents to help oncologists treat cancer patients in early malignant stages. Advantages: -Reduced side effects -Early diagnosis Potential Applications: -Chemotherapy drugs -Radioimaging agents

Website

https://prf.flintbox.com/technologies/8867D78FC238498DA169079A1F24946B

Advantages

  • Reduced Side Effect
  • Early Diagnosis

Potential Applications

  • Chemotherapy Drugs
  • RadioImaging Agents

Contact Information

Name: Brooke L Beier

Email: blbeier@prf.org

Phone: 810-571-2387